NRx Pharmaceuticals (NASDAQ:NRXP) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Monday,Benzinga reports. They currently have a $19.00 target price on the stock. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.75) EPS and FY2025 earnings at ($0.08) EPS.

Several other research firms have also recently commented on NRXP. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $1.29 on Monday. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $7.33. The stock’s fifty day moving average is $1.37 and its 200-day moving average is $2.13. The firm has a market capitalization of $15.60 million, a price-to-earnings ratio of -0.60 and a beta of 1.27.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC acquired a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned approximately 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.